Cipla gets USFDA approval for Metoprolol ER Tablets
Mumbai: Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Metoprolol ER Tablets 50mg, 100mg, 200mg from the United States Food and Drug Administration (US FDA).
Cipla’s Metoprolol ER Tablets 50mg, 100mg, 200mg is an AB-rated generic therapeutic equivalent version of Aralez Pharmaceuticals, Inc.’s, Toprol XL. It is a beta1-selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure, Angina Pectoris, heart failure for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin.
According to IQVIA (IMS Health), Toprol XL and its generic equivalents had U.S. sales of approximately $464M for the 12-month period ending Aug 2018.
Read Also: Cipla gets USFDA approval for Hypertension, Cardiac drug
Cipla’s Metoprolol ER Tablets 50mg, 100mg, 200mg is an AB-rated generic therapeutic equivalent version of Aralez Pharmaceuticals, Inc.’s, Toprol XL. It is a beta1-selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure, Angina Pectoris, heart failure for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin.
According to IQVIA (IMS Health), Toprol XL and its generic equivalents had U.S. sales of approximately $464M for the 12-month period ending Aug 2018.
Read Also: Cipla gets USFDA approval for Hypertension, Cardiac drug
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd